Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 4
2005 4
2006 4
2007 5
2008 6
2009 7
2010 10
2011 7
2012 5
2013 5
2014 11
2015 13
2016 6
2017 5
2018 3
2019 4
2020 5
2021 10
2022 9
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

120 results

Results by year

Filters applied: . Clear all
Page 1
Diffuse Large B-Cell Lymphoma in the HIV Setting.
Huguet M, Navarro JT, Moltó J, Ribera JM, Tapia G. Huguet M, et al. Among authors: molto j. Cancers (Basel). 2023 Jun 15;15(12):3191. doi: 10.3390/cancers15123191. Cancers (Basel). 2023. PMID: 37370801 Free PMC article. Review.
Clinical Pharmacology of the Synthetic Cathinone Mephedrone.
Papaseit E, Moltó J, Muga R, Torrens M, de la Torre R, Farré M. Papaseit E, et al. Among authors: molto j. Curr Top Behav Neurosci. 2017;32:313-331. doi: 10.1007/7854_2016_61. Curr Top Behav Neurosci. 2017. PMID: 28012094 Review.
Hodgkin Lymphoma in People Living with HIV.
Navarro JT, Moltó J, Tapia G, Ribera JM. Navarro JT, et al. Among authors: molto j. Cancers (Basel). 2021 Aug 29;13(17):4366. doi: 10.3390/cancers13174366. Cancers (Basel). 2021. PMID: 34503176 Free PMC article. Review.
Clinical utility of maraviroc.
Parra J, Portilla J, Pulido F, Sánchez-de la Rosa R, Alonso-Villaverde C, Berenguer J, Blanco JL, Domingo P, Dronda F, Galera C, Gutiérrez F, Kindelán JM, Knobel H, Leal M, López-Aldeguer J, Mariño A, Miralles C, Moltó J, Ortega E, Oteo JA. Parra J, et al. Among authors: molto j. Clin Drug Investig. 2011;31(8):527-542. doi: 10.2165/11590700-000000000-00000. Clin Drug Investig. 2011. PMID: 21595497 Review.
[Pharmacological interactions with darunavir].
Moltó J, Valle M, Clotet B. Moltó J, et al. Enferm Infecc Microbiol Clin. 2008 Oct;26 Suppl 10:43-50. doi: 10.1016/s0213-005x(08)76553-4. Enferm Infecc Microbiol Clin. 2008. PMID: 19195459 Review. Spanish.
Aging in HIV-Infected Subjects: A New Scenario and a New View.
Negredo E, Back D, Blanco JR, Blanco J, Erlandson KM, Garolera M, Guaraldi G, Mallon P, Moltó J, Serra JA, Clotet B. Negredo E, et al. Among authors: molto j. Biomed Res Int. 2017;2017:5897298. doi: 10.1155/2017/5897298. Epub 2017 Dec 21. Biomed Res Int. 2017. PMID: 29430462 Free PMC article. Review.
Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM).
Gonzalez-Cao M, Puertolas T, Riveiro M, Muñoz-Couselo E, Ortiz C, Paredes R, Podzamczer D, Manzano JL, Molto J, Revollo B, Carrera C, Mateu L, Fancelli S, Espinosa E, Clotet B, Martinez-Picado J, Cerezuela P, Soria A, Marquez I, Mandala M, Berrocal A; Spanish Melanoma Group (GEM). Gonzalez-Cao M, et al. Among authors: molto j. J Immunother Cancer. 2021 Mar;9(3):e001664. doi: 10.1136/jitc-2020-001664. J Immunother Cancer. 2021. PMID: 33782108 Free PMC article. Review.
Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial.
Bailón L, Llano A, Cedeño S, Escribà T, Rosás-Umbert M, Parera M, Casadellà M, Lopez M, Pérez F, Oriol-Tordera B, Ruiz-Riol M, Coll J, Perez F, Rivero À, Leselbaum AR, McGowan I, Sengupta D, Wee EG, Hanke T, Paredes R, Alarcón-Soto Y, Clotet B, Noguera-Julian M, Brander C, Molto J, Mothe B; AELIX002 Study Group. Bailón L, et al. Among authors: molto j. Nat Med. 2022 Dec;28(12):2611-2621. doi: 10.1038/s41591-022-02060-2. Epub 2022 Oct 27. Nat Med. 2022. PMID: 36302893 Clinical Trial.
Plasma proteomic profiling identifies CD33 as a marker of HIV control in natural infection and after therapeutic vaccination.
Duran-Castells C, Prats A, Oriol-Tordera B, Llano A, Galvez C, Martinez-Picado J, Ballana E, Garcia-Vidal E, Clotet B, Muñoz-Moreno JA, Hanke T, Moltó J, Mothe B, Brander C, Ruiz-Riol M. Duran-Castells C, et al. Among authors: molto j. EBioMedicine. 2023 Sep;95:104732. doi: 10.1016/j.ebiom.2023.104732. Epub 2023 Jul 26. EBioMedicine. 2023. PMID: 37506557 Free PMC article. Clinical Trial.
120 results